Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 15/20 | 0.46 |
| ▸ | THRB | P10828 | 15/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | PCNA | P12004 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3908141 | 0.88 | THRA (0.49) | THRATHRBMAPTKMT2A | |
| SCHEMBL3146055 | 0.88 | THRA (0.48) | THRATHRBHDAC1 | |
| SCHEMBL3131477 | 0.83 | THRB (0.48) | THRATHRBPCNAMAPTKMT2A | |
| SCHEMBL3908329 | 0.82 | THRA (0.44) | THRATHRBHDAC1MAPTMEN1 | |
| SCHEMBL3910714 | 0.81 | KMT2A (0.46) | THRATHRBMAPTMEN1KMT2A | |
| SCHEMBL3909957 | 0.81 | KMT2A (0.46) | THRATHRBMAPTMEN1KMT2A | |
| SCHEMBL3130002 | 0.80 | THRA (0.39) | THRATHRB | |
| SCHEMBL3136070 | 0.77 | THRA (0.45) | THRATHRBMAPTMEN1KMT2A | |
| SCHEMBL14386131 | 0.77 | THRA (0.42) | THRATHRBPCNAMAPTKMT2A | |
| SCHEMBL3142103 | 0.76 | THRB (0.44) | THRATHRBPCNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | THRA 4/4885THRB 6/4885HDAC1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.